Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis

被引:39
作者
D'Antonio, F. [1 ]
Marinceu, D. [2 ]
Prasad, S. [3 ]
Khalil, A. [3 ,4 ,5 ,6 ]
机构
[1] Univ G dAnnunzio, Ctr Fetal Care & High Risk Pregnancy, Chieti, Italy
[2] York Hosp, Dept Obstet & Gynecol, York, England
[3] Univ London, St Georges Univ Hosp NHS Fdn Trust, Fetal Med Unit, London, England
[4] St Georges Univ London, Mol & Clin Sci Res Inst, Vasc Biol Res Ctr, London, England
[5] Univ Liverpool, Liverpool Womens Hosp, Fetal Med Unit, Liverpool, England
[6] St Georges Univ Hosp NHS Fdn Trust, Dept Obstet & Gynaecol, Fetal Med Unit, Blackshaw Rd, London SW17 0QT, England
关键词
congenital CMV infection; cytomegalovirus; effectiveness; pregnancy; safety; symptomatic infection; valacyclovir; VALACICLOVIR; FETUSES;
D O I
10.1002/uog.26136
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
ObjectiveUniversal screening for cytomegalovirus (CMV) infection in pregnancy is not recommended in most countries. One of the major deterrents is the lack of effective prenatal therapy. The role of valacyclovir therapy in reducing the risk of vertical transmission, symptomatic congenital CMV infection and adverse outcome is controversial. The main aim of this systematic review and meta-analysis was to investigate the safety and effectiveness of prenatal valacyclovir therapy in pregnancies with maternal CMV infection. MethodsMEDLINE, EMBASE and Cochrane databases and were searched. The inclusion criteria were pregnancy with confirmed maternal CMV infection, treated or untreated with valacyclovir. The primary outcome was the incidence of congenital CMV infection confirmed by a positive CMV polymerase chain reaction result of the amniotic fluid. The secondary outcomes were symptomatic and asymptomatic infection, perinatal death, termination of pregnancy, anomalies detected on follow-up ultrasound, on fetal magnetic resonance imaging or at birth, severe and mild-to-moderate symptoms due to congenital CMV infection, neurological, visual and hearing symptoms, and adverse events related to valacyclovir. Risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2) or Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool, as appropriate. Head-to-head meta-analyses were used to compare the risk of each of the explored outcomes according to whether pregnancies with maternal CMV infection were treated with prenatal valacyclovir therapy. ResultsEight studies (620 women) were included. Pregnancies treated with valacyclovir had a significantly lower risk of congenital CMV infection compared with those not receiving valacyclovir (three studies; 325 fetuses; pooled odds ratio (OR), 0.37 (95% CI, 0.21-0.64); I-2 = 0%; P < 0.001). When stratifying the analysis according to gestational age at maternal infection, the risk of vertical transmission was significantly lower in pregnancies receiving valacyclovir following first-trimester maternal infection (three studies; 184 fetuses; pooled OR, 0.34 (95% CI, 0.15-0.74); I-2 = 20.9%; P = 0.001), while there was no significant difference between the two groups in those acquiring CMV infection in the periconceptional period or in the third trimester of pregnancy. Only one study reported on the risk of vertical transmission in women infected in the second trimester, demonstrating a lower risk of congenital infection in women taking valacyclovir, although this was based on a small number of cases. Pregnancies treated with valacyclovir therapy had an increased likelihood of asymptomatic congenital CMV infection compared with those not receiving valacyclovir (two studies; 132 fetuses; pooled OR, 2.98 (95% CI, 1.18-7.55); I-2 = 0%; P = 0.021), while there was no significant difference between the two groups in the risk of perinatal death (P = 0.923), termination of pregnancy (P = 0.089), anomalies detected at follow-up imaging assessment during pregnancy or at birth (P = 0.934) and symptoms due to CMV infection in the newborn (P = 0.092). The occurrence of all adverse events in pregnant individuals taking valacyclovir was 3.17% (95% CI, 1.24-5.93%) (six studies; 210 women), with 1.71% (95% CI, 0.41-3.39%) experiencing acute renal failure, which resolved after discontinuation of the drug. On GRADE assessment, the quality of evidence showing that valacyclovir reduced the risk of congenital CMV infection and adverse perinatal outcome was very low. ConclusionsPrenatal valacyclovir administration in pregnancies with maternal CMV infection reduces the risk of congenital CMV infection. Further evidence is needed to elucidate whether valacyclovir can affect the course of infection in the fetus and the risk of symptomatic fetal or neonatal infection. (c) 2022 International Society of Ultrasound in Obstetrics and Gynecology.
引用
收藏
页码:436 / 444
页数:9
相关论文
共 50 条
[31]   Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis [J].
Frimpong, Augustina ;
Thiam, Laty Gaye ;
Arko-Boham, Benjamin ;
Owusu, Ewurama Dedea Ampadu ;
Adjei, George O. .
BMC INFECTIOUS DISEASES, 2018, 18
[32]   Effectiveness and safety of percutaneous endoscopic debridement and drainage for spinal infections: a systematic review and meta-analysis [J].
Zhou, Guozhong ;
Liu, Xiaorong ;
Liang, Zhi ;
Chen, Xuesong ;
Song, Chao .
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2025, 20 (01)
[33]   In vivo effectiveness and safety of probiotics on prophylaxis and treatment of oral candidiasis: a systematic review and meta-analysis [J].
Hu, Lijun ;
Zhou, Mimi ;
Young, Andrew ;
Zhao, Weiwei ;
Yan, Zhimin .
BMC ORAL HEALTH, 2019, 19 (1)
[34]   The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis [J].
Cui, Yuying ;
Guo, Yingxue .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (04) :843-851
[35]   Effectiveness and safety of COVID-19 vaccine in pregnant women: A systematic review with meta-analysis [J].
Tormen, Mara ;
Taliento, Cristina ;
Salvioli, Stefano ;
Piccolotti, Irene ;
Scutiero, Gennaro ;
Cappadona, Rosaria ;
Greco, Pantaleo .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2023, 130 (04) :348-357
[36]   Effectiveness and Safety of Iguratimod in Treating Primary Sjogren's Syndrome: A Systematic Review and Meta-Analysis [J].
Pu, Jincheng ;
Wang, Xuan ;
Riaz, Farooq ;
Zhang, Tongyangzi ;
Gao, Ronglin ;
Pan, Shengnan ;
Wu, Zhenzhen ;
Liang, Yuanyuan ;
Zhuang, Shuqi ;
Tang, Jianping .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[37]   In vivo effectiveness and safety of probiotics on prophylaxis and treatment of oral candidiasis: a systematic review and meta-analysis [J].
Lijun Hu ;
Mimi Zhou ;
Andrew Young ;
Weiwei Zhao ;
Zhimin Yan .
BMC Oral Health, 19
[38]   Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis [J].
Augustina Frimpong ;
Laty Gaye Thiam ;
Benjamin Arko-Boham ;
Ewurama Dedea Ampadu Owusu ;
George O. Adjei .
BMC Infectious Diseases, 18
[39]   A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults [J].
Xu, Kun ;
Wang, Zihan ;
Qin, Maorong ;
Gao, Yangyu ;
Luo, Na ;
Xie, Wanting ;
Zou, Yihan ;
Wang, Jie ;
Ma, Xingming .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[40]   Effectiveness and safety of carboxytocin versus oxytocin in preventing postpartum hemorrhage: A systematic review and meta-analysis [J].
Sun, Haiyan ;
Xu, Lei ;
Li, Yu ;
Zhao, Shurong .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (04) :889-901